Unbound (bioavailable) IGF1 enhances somatic growth

DMM Disease Models and Mechanisms

Volumn 4, Issue 5, 2011, Pages 649-658

  Elis, Sebastien ^a   Wu, Yingjie ^a   Courtland, Hayden William ^a   Cannata, Dara ^a   Sun, Hui ^a   Beth On, Mordechay ^a   Liu, Chengyu ^b   Jasper, Hector ^c   Domené, Horacio ^c   Karabatas, Liliana ^c   Guida, Clara ^c   Basta Pljakic, Jelena ^d   Cardoso, Luis ^d   Rosen, Clifford J ^e   Frystyk, Jan ^f   Yakar, Shoshana ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^d City University of New York   (United States)

^e Maine Medical Center Research Institute   (United States)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; MUTANT PROTEIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BIOAVAILABILITY; BODY COMPOSITION; BODY GROWTH; BODY HEIGHT; BODY WEIGHT; COMPLEX FORMATION; CONTROLLED STUDY; FEMALE; GENE TARGETING; GROWTH HORMONE BLOOD LEVEL; KIDNEY HYPERTROPHY; LEAN BODY WEIGHT; MAMMARY GLAND; MOUSE; NONHUMAN; ORGAN GROWTH; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; SPLENOMEGALY; UTERUS; WILD TYPE;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; BIOLOGICAL AVAILABILITY; BODY SIZE; BODY WEIGHT; FEMALE; GENE KNOCK-IN TECHNIQUES; GROWTH AND DEVELOPMENT; GROWTH HORMONE; INSULIN-LIKE GROWTH FACTOR I; MAMMARY GLANDS, ANIMAL; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MODELS, ANIMAL; MOLECULAR SEQUENCE DATA; MULTIPROTEIN COMPLEXES; ORGAN SIZE; OSTEOGENESIS; PROTEIN BINDING; UTERUS;

MUS;

EID: 80052281596     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.006775     Document Type: Article

References (51)

1. Baker, J., Liu, J. P., Robertson, E. J. and Efstratiadis, A. (1993). Role of insulin-like growth factors in embryonic and postnatal growth. Cell 75, 73-82. (Pubitemid 23306022)
2. Ballard, F. J., Francis, G. L., Ross, M., Bagley, C. J., May, B. and Wallace, J. C. (1987). Natural and synthetic forms of insulin-like growth factor-1 (IGF-1) and the potent derivative, destripeptide IGF-1:Biological activities and receptor binding. Biochem. Biophys. Res. Commun. 149, 398-404. (Pubitemid 18022993)
3. Ballard, F. J., Ross, M., Upton, F. M. and Francis, G. L. (1988). Specific binding of insulin-like growth factors 1 and 2 to the type 1 and type 2 receptors respectively. Biochem. J. 249, 721-726. (Pubitemid 18042792)
4. Ballard, F. J., Knowles, S. E., Walton, P. E., Edson, K., Owens, P. C., Mohler, M. A. and Ferraiolo, B. L. (1991). Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I), IGF-II and des(1-3)IGF-I in rats. J. Endocrinol. 128, 197-204.
5. Bastian, S. E., Walton, P. E., Wallace, J. C. and Ballard, F. J. (1993). Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I) and an analogue LR3IGF-I in pregnant rats. J. Endocrinol. 138, 327-336. (Pubitemid 23300710)
6. Baxter, R. C. (2000). Insulin-like growth factor (IGF)-binding proteins:Interactions with IGFs and intrinsic bioactivities. Am. J. Physiol. Endocrinol. Metab. 278, E967-E976.
7. Baxter, R. C. and Martin, J. L. (1989). Structure of the Mr 140,000 growth hormone-dependent insulin-like growth factor binding protein complex:Determination by reconstitution and affinity-labeling. Proc. Natl. Acad. Sci. USA 86, 6898-6902. (Pubitemid 19240839)
8. Bayne, M. L., Applebaum, J., Underwood, D., Chicchi, G. G., Green, B. G., Hayes, N. S. and Cascieri, M. A. (1989). The C region of human insulin-like growth factor (IGF) I is required for high affinity binding to the type 1 IGF receptor. J. Biol. Chem. 264, 11004-11008. (Pubitemid 19168823)
9. Butterfield, G. E., Thompson, J., Rennie, M. J., Marcus, R., Hintz, R. L. and Hoffman, A. R. (1997). Effect of rhGH and rhIGF-I treatment on protein utilization in elderly women. Am. J. Physiol. 272, E94-E99.
10. Chen, J. W., Ledet, T., Orskov, H., Jessen, N., Lund, S., Whittaker, J., De Meyts, P., Larsen, M. B., Christiansen, J. S. and Frystyk, J. (2003). A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. Am. J. Physiol. Endocrinol. Metab. 284, E1149-E1155. (Pubitemid 36617461)
11. Cooke, R. M., Harvey, T. S. and Campbell, I. D. (1991). Solution structure of human insulin-like growth factor 1, a nuclear magnetic resonance and restrained molecular dynamics study. Biochemistry 30, 5484-5491.
12. Coolican, S. A, Samuel, D. S., Ewton, D. Z., McWade, F. J. and Florini, J. R. (1997). The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. J. Biol. Chem. 272, 6653-6662. (Pubitemid 27118151)
13. Courtland, H. W., Demambro, V., Maynard, J., Sun, H., Elis, S., Rosen, C. and Yakar, S. (2010). Sex-specific regulation of body size and bone slenderness by the acid labile subunit. J. Bone Miner. Res. 25, 2059-2068.
14. Crist, D. M. and Hill, J. M. (1990). Diet and insulinlike growth factor I in relation to body composition in women with exercise-induced hypothalamic amenorrhea. J. Am. Coll. Nutr. 9, 200-204.
15. Domene, H. M., Bengolea, S. V., Martinez, A. S., Ropelato, M. G., Pennisi, P., Scaglia, P., Heinrich, J. J. and Jasper, H. G. (2004). Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene. N. Engl. J. Med. 350, 570-577. (Pubitemid 38160787)
16. Domene, H. M., Hwa, V., Argente, J., Wit, J. M., Camacho-Hubner, C., Jasper, H. G., Pozo, J., Van Duyvenvoorde, H. A., Yakar, S., Fofanova-Gambetti, O. V. et al. (2009). Human acid-labile subunit deficiency:Clinical, endocrine and metabolic consequences. Horm. Res. 72, 129-141.
17. Flint, D. J., Tonner, E., Beattie, J. and Gardner, M. (1994). Several insulin-like growth factor-I analogues and complexes of insulin-like growth factors-I and -II with insulin-like growth factor-binding protein-3 fail to mimic the effect of growth hormone upon lactation in the rat. J. Endocrinol. 140, 211-216. (Pubitemid 24110107)
18. Forbes, K. and Westwood, M. (2008). The IGF axis and placental function. a mini review. Horm. Res. 69, 129-137. (Pubitemid 351161040)
19. Francis, G. L., McMurtry, J. P., Johnson, R. J. and Ballard, F. J. (1990). Plasma clearance of chicken and human insulin-like growth factor-I and their association with circulating binding proteins in chickens. J. Endocrinol. 124, 361-370. (Pubitemid 20070442)
20. Frystyk, J. (2005). Aging somatotropic axis:Mechanisms and implications of insulin-like growth factor-related binding protein adaptation. Endocrinol. Metab. Clin. North Am. 34, 865-876, viii.
21. Gillespie, C., Read, L. C., Bagley, C. J. and Ballard, F. J. (1990). Enhanced potency of truncated insulin-like growth factor-I (des(1-3)IGF-I) relative to IGF-I in lit/lit mice. J. Endocrinol. 127, 401-405.
22. Hadsell, D. L., Greenberg, N. M., Fligger, J. M., Baumrucker, C. R. and Rosen, J. M. (1996). Targeted expression of des(1-3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinology 137, 321-330. (Pubitemid 26005007)
23. Jepsen, K. J., Hu, B., Tommasini, S. M., Courtland, H. W., Price, C., Terranova, C. J. and Nadeau, J. H. (2007). Genetic randomization reveals functional relationships among morphologic and tissue-quality traits that contribute to bone strength and fragility. Mamm. Genome 18, 492-507. (Pubitemid 47360414)
24. Kaaks, R. (2004). Nutrition, insulin, IGF-1 metabolism and cancer risk:A summary of epidemiological evidence. Novartis Found. Symp. 262, 247-260; discussion 260-268.
25. King, R., Wells, J. R., Krieg, P., Snoswell, M., Brazier, J., Bagley, C. J., Wallace, J. C., Ballard, F. J., Ross, M. and Francis, G. L. (1992). Production and characterization of recombinant insulin-like growth factor-I (IGF-I) and potent analogues of IGF-I, with Gly or Arg substituted for Glu3, following their expression in Escherichia coli as fusion proteins. J. Mol. Endocrinol. 8, 29-41.
26. Kreitschmann-Andermahr, I., Suarez, P., Jennings, R., Evers, N. and Brabant, G. (2010). GH/IGF-I regulation in obesity-mechanisms and practical consequences in children and adults. Horm. Res. Paediatr. 73, 153-160.
27. Lemmey, A. B., Martin, A. A., Read, L. C., Tomas, F. M., Owens, P. C. and Ballard, F. J. (1991). IGF-I and the truncated analogue des-(1-3)IGF-I enhance growth in rats after gut resection. Am. J. Physiol. 260, E213-E219.
28. Liu, J. L., Grinberg, A., Westphal, H., Sauer, B., Accili, D., Karas, M. and LeRoith, D. (1998). Insulin-like growth factor-I affects perinatal lethality and postnatal development in a gene dosage-dependent manner:Manipulation using the Cre/loxP system in transgenic mice. Mol. Endocrinol. 12, 1452-1462. (Pubitemid 128496205)
29. Liu, P., Jenkins, N. A. and Copeland, N. G. (2003). A highly efficient recombineering-based method for generating conditional knockout mutations. Genome Res. 13, 476-484. (Pubitemid 36395405)
30. Mathews, L. S., Hammer, R. E., Behringer, R. R., D'Ercole, A. J., Bell, G. I., Brinster, R. L. and Palmiter, R. D. (1988). Growth enhancement of transgenic mice expressing human insulin-like growth factor I. Endocrinology 123, 2827-2833. (Pubitemid 19012801)
31. McCusker, R. H., Kaleko, M. and Sackett, R. L. (1998). Multivalent cations and ligand affinity of the type 1 insulin-like growth factor receptor on P2A2-LISN muscle cells. J. Cell Physiol. 176, 392-401. (Pubitemid 28319723)
32. Mohan, S. and Baylink D. J. (2002). IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J. Endocrinol. 175, 19-31. (Pubitemid 35276583)
33. Ning, Y., Schuller, A. G., Bradshaw, S., Rotwein, P., Ludwig, T., Frystyk, J. and Pintar, J. E. (2006). Diminished growth and enhanced glucose metabolism in triple knockout mice containing mutations of insulin-like growth factor binding protein-3, -4, and -5. Mol. Endocrinol. 20, 2173-2186. (Pubitemid 44286712)
34. Pennisi, P., Gavrilova, O., Setser-Portas, J., Jou, W., Santopietro, S., Clemmons, D., Yakar, S. and LeRoith, D. (2006). Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus. Endocrinology 147, 2619-2630. (Pubitemid 43764594)
35. Ross, M., Francis, G. L., Szabo, L., Wallace, J. C. and Ballard, F. J. (1989). Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1. Biochem. J. 258, 267-272. (Pubitemid 19062278)
36. Sato, A., Nishimura, S., Ohkubo, T., Kyogoku, Y., Koyama, S., Kobayashi, M., Yasuda, T. and Kobayashi, Y. (1993). Three-dimensional structure of human insulin-like growth factor-I (IGF-I) determined by 1H-NMR and distance geometry. Int. J. Pept. Protein Res. 41, 433-440. (Pubitemid 23144737)
37. Stratikopoulos, E., Szabolcs, M., Dragatsis, I., Klinakis, A. and Efstratiadis, A. (2008). The hormonal action of IGF1 in postnatal mouse growth. Proc. Natl. Acad. Sci. USA 105, 19378-19383.
38. Sun, B. F., Kobayashi, H., Le, N., Yoo, T. M., Drumm, D., Paik, C. H., McAfee, J. G. and Carrasquillo, J. A. (1997). Biodistribution of 125I-labeled des(1-3) insulin-like growth factor I in tumor-bearing nude mice and its in vitro catabolism. Cancer Res. 57, 2754-2759. (Pubitemid 27283790)
39. Szabo, L., Mottershead, D. G., Ballard, F. J. and Wallace, J. C. (1988). The bovine insulin-like growth factor (IGF) binding protein purified from conditioned medium requires the N-terminal tripeptide in IGF-1 for binding. Biochem. Biophys. Res. Commun. 151, 207-214.
40. Thompson, J. L., Butterfield, G. E., Marcus, R., Hintz, R. L., Van Loan, M., Ghiron, L. and Hoffman, A. R. (1995). The effects of recombinant human insulin-like growth factor-I and growth hormone on body composition in elderly women. J. Clin. Endocrinol. Metab. 80, 1845-1852.
41. Wakai, K., Suzuki, K., Ito, Y., Watanabe, Y., Inaba, Y., Tajima, K., Nakachi, K. and Tamakoshi, A. (2009). Time spent walking or exercising and blood levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3):A large-scale cross-sectional study in the Japan Collaborative Cohort study. Asian Pac. J. Cancer Prev. 10 Suppl, 23-27.
42. Woods, K. A., Camacho-Hubner, C., Savage, M. O. and Clark, A. J. (1996). Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N. Engl. J. Med. 335, 1363-1367. (Pubitemid 26360455)
43. Yakar, S., Liu, J. L., Fernandez, A. M., Wu, Y., Schally, A. V., Frystyk, J., Chernausek, S. D., Mejia, W. and Le Roith, D. (2001). Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes 50, 1110-1118. (Pubitemid 32374542)
44. Yakar, S., Rosen, C. J., Beamer, W. G., Ackert-Bicknell, C. L., Wu, Y., Liu, J. L., Ooi, G. T., Setser, J., Frystyk, J., Boisclair, Y. R. et al. (2002a). Circulating levels of IGF-1 directly regulate bone growth and density. J. Clin. Invest. 110, 771-781.
45. Yakar, S., Wu, Y., Setser, J. and Rosen, C. J. (2002b). The role of circulating IGF-I:Lessons from human and animal models. Endocrine 19, 239-248. (Pubitemid 36250303)
46. Yakar, S., Setser, J., Zhao, H., Stannard, B., Haluzik, M., Glatt, V., Bouxsein, M. L., Kopchick, J. J. and LeRoith, D. (2004). Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J. Clin. Invest. 113, 96-105. (Pubitemid 38541636)
47. Yakar, S., Kim, H., Zhao, H., Toyoshima, Y., Pennisi, P., Gavrilova, O. and LeRoith, D. (2005a). The growth hormone-insulin like growth factor axis revisited:Lessons from IGF-1 and IGF-1 receptor gene targeting. Pediatr. Nephrol. 20, 251-254. (Pubitemid 40309926)
48. Yakar, S., Leroith, D. and Brodt, P. (2005b). The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression:Lessons from animal models. Cytokine Growth Factor Rev. 16, 407-420. (Pubitemid 41022011)
49. Yakar, S., Bouxsein, M. L., Canalis, E., Sun, H., Glatt, V., Gundberg, C., Cohen, P., Hwang, D., Boisclair, Y., Leroith, D. et al. (2006). The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone. J. Endocrinol. 189, 289-299.
50. Yakar, S., Canalis, E., Sun, H., Mejia, W., Kawashima, Y., Nasser, P., Courtland, H. W., Williams, V., Bouxsein, M., Rosen, C. et al. (2009a). Serum IGF-1 determines skeletal strength by regulating subperiosteal expansion and trait interactions. J. Bone Miner. Res. 24, 1481-1492.
51. Yakar, S., Rosen, C. J., Bouxsein, M. L., Sun, H., Mejia, W., Kawashima, Y., Wu, Y., Emerton, K., Williams, V., Jepsen, K. et al. (2009b). Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism. FASEB J. 23, 709-719.